Ultra-Rapid Cycling Bipolar Disorder: A Case Report

Ultra-rapid cycling disorder, in which mood episodes shift over days rather than months, sits at one of the most difficult ends of the bipolar spectrum. It resists standard treatment, tends to worsen with antidepressants, and has very little long-term outcome data to guide clinical decisions. We report the case of a 51-year-old woman whose ultra-rapid cycling bipolar disorder was tracked for 130 weeks. She underwent trials of multiple mood stabilizers, five second-generation antipsychotics, and two courses of electroconvulsive therapy (ECT), none of which produced sustained remission. Clozapine brought the most meaningful improvement seen across the entire treatment period but had to be stopped because of sialorrhea and weight gain. The patient described the sialorrhea as feeling like she was drowning in her own saliva, a symptom that, while pharmacologically manageable, was not addressed in time to preserve the treatment. She was subsequently transitioned to long-acting injectable aripiprazole, primarily to address adherence. Ultra-rapid cycling bipolar disorder is genuinely hard to treat, and this case shows what that looks like in practice. Sustained remission may require earlier procedural intervention, more aggressive management of comorbidities, and a willingness to consider agents, including clozapine, that are often reserved as a last resort.